NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...
First national guideline recommendation for Shield paves the way for improved patient access and additional major guideline inclusions NCCN guidelines point to landmark ECLIPSE Study showing efficacy ...
The National Comprehensive Cancer Network celebrated its 30th anniversary with a series of presentations on cancer care practice changes—in both treatment and administration—plus new research, and ...
PLYMOUTH MEETING, PA [December 4, 2025] — The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven ...
Today, the National Comprehensive Cancer Network ® (NCCN ®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast ...
Speakers explore how we can better protect the heroes who protect us all. WASHINGTON, Dec. 9, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer ...
New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...
Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, effective in first-line and subsequent therapies, especially for brain metastases. TRUST-I and TRUST-II trials showed high ...
In this retrospective cohort analysis, researchers aimed to identify key predictors of trial enrollment among cancer patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback